Literature DB >> 33765029

Use of gastric acid-suppressive agents increases the risk of dementia in patients with upper gastrointestinal disease: A population-based retrospective cohort study.

Hsiu-Chen Lin1,2, Kuan-Tzu Huang3,4, Hsiu-Li Lin5, Yow-Sheng Uang3, Yi Ho3, Joseph Jordan Keller6, Li-Hsuan Wang3,7.   

Abstract

BACKGROUND: Prescriptions for gastric acid-suppressive agents, including proton-pump inhibitors (PPIs) and histamine type-2 receptor antagonists (H2RAs), are rising. However, little data exist regarding their association with dementia in the Asian population. The objective of this study was thus to investigate the impact of the use of PPIs and H2RAs on the risk of dementia in an Asian population with upper gastrointestinal disease (UGID).
METHODS: We conducted a population-based retrospective cohort study with a 10-year follow-up using data from 2000 to 2015 derived from Taiwan's Longitudinal Health Insurance Database. We included 6711 patients with UGID receiving gastric acid-suppressive agents, 6711 patients with UGID not receiving agents, and 6711 patients without UGID or treatment thereof, all at least 20 years of age. Groups were matched for age, sex, and index date. The association between gastric acid-suppressive agent use and dementia was analyzed using a Cox proportional hazards regression model adjusted for potential confounders.
RESULTS: The adjusted hazard ratio (aHR) of dementia for patients with UGID receiving gastric acid-suppressive agents compared with patients with UGID without gastric acid-suppressive agents was 1.470 (95% confidence interval [CI] 1.267-1.705, p < 0.001). Both PPIs and H2RAs increase the risk of dementia (PPIs: aHR 1.886 [95% CI 1.377-2.582], p < 0.001; H2RAs: aHR 1.357 [95% CI 1.098-1.678], p < 0.01), with PPIs exhibiting significantly greater risk (aHR 1.456 [95% CI 1.022-2.075], p < 0.05).
CONCLUSIONS: Our results demonstrate an increased risk of dementia in patients with UGID receiving gastric acid-suppressive agents, including PPIs and H2RAs, and the use of PPIs was associated with a significantly greater risk than H2RA use.

Entities:  

Year:  2021        PMID: 33765029      PMCID: PMC7993796          DOI: 10.1371/journal.pone.0249050

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  15 in total

1.  The worldwide economic impact of dementia 2010.

Authors:  Anders Wimo; Linus Jönsson; John Bond; Martin Prince; Bengt Winblad
Journal:  Alzheimers Dement       Date:  2013-01       Impact factor: 21.566

2.  Risk of dementia in elderly patients with the use of proton pump inhibitors.

Authors:  Britta Haenisch; Klaus von Holt; Birgitt Wiese; Jana Prokein; Carolin Lange; Annette Ernst; Christian Brettschneider; Hans-Helmut König; Jochen Werle; Siegfried Weyerer; Melanie Luppa; Steffi G Riedel-Heller; Angela Fuchs; Michael Pentzek; Dagmar Weeg; Horst Bickel; Karl Broich; Frank Jessen; Wolfgang Maier; Martin Scherer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-10-24       Impact factor: 5.270

3.  Anticholinergic drug use and risk for dementia: target for dementia prevention.

Authors:  Frank Jessen; Hanna Kaduszkiewicz; Moritz Daerr; Horst Bickel; Michael Pentzek; Steffi Riedel-Heller; Michael Wagner; Siegfried Weyerer; Birgitt Wiese; Hendrik van den Bussche; Karl Broich; Wolfgang Maier
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-10-20       Impact factor: 5.270

4.  Activation of microglia acidifies lysosomes and leads to degradation of Alzheimer amyloid fibrils.

Authors:  Amitabha Majumdar; Dana Cruz; Nikiya Asamoah; Adina Buxbaum; Istvan Sohar; Peter Lobel; Frederick R Maxfield
Journal:  Mol Biol Cell       Date:  2007-02-21       Impact factor: 4.138

5.  The association between cognition and histamine-2 receptor antagonists in African Americans.

Authors:  Malaz Boustani; Kathleen S Hall; Kathleen A Lane; Hisham Aljadhey; Sujuan Gao; Frederick Unverzagt; Michael D Murray; Adesola Ogunniyi; Hugh Hendrie
Journal:  J Am Geriatr Soc       Date:  2007-08       Impact factor: 5.562

Review 6.  Alzheimer's disease and the amyloid-beta peptide.

Authors:  M Paul Murphy; Harry LeVine
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

7.  Long-term anticholinergic use and the aging brain.

Authors:  Xueya Cai; Noll Campbell; Babar Khan; Christopher Callahan; Malaz Boustani
Journal:  Alzheimers Dement       Date:  2012-11-22       Impact factor: 21.566

8.  Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs.

Authors:  Francesca Luciani; Massimo Spada; Angelo De Milito; Agnese Molinari; Licia Rivoltini; Annalisa Montinaro; Manuela Marra; Luana Lugini; Mariantonia Logozzi; Francesco Lozupone; Cristina Federici; Elisabetta Iessi; Giorgio Parmiani; Giuseppe Arancia; Filippo Belardelli; Stefano Fais
Journal:  J Natl Cancer Inst       Date:  2004-11-17       Impact factor: 13.506

9.  Risk of dementia from proton pump inhibitor use in Asian population: A nationwide cohort study in Taiwan.

Authors:  Shu-Yu Tai; Chen-Yu Chien; Deng-Chyang Wu; Kun-Der Lin; Bo-Lin Ho; Yu-Han Chang; Yang-Pei Chang
Journal:  PLoS One       Date:  2017-02-15       Impact factor: 3.240

10.  The proton-pump inhibitor lansoprazole enhances amyloid beta production.

Authors:  Nahuai Badiola; Victor Alcalde; Albert Pujol; Lisa-Marie Münter; Gerd Multhaup; Alberto Lleó; Mireia Coma; Montserrat Soler-López; Patrick Aloy
Journal:  PLoS One       Date:  2013-03-08       Impact factor: 3.240

View more
  2 in total

1.  Associations between proton pump inhibitors and Alzheimer's disease: a nested case-control study using a Korean nationwide health screening cohort.

Authors:  Hyo Geun Choi; Joo-Hee Kim; Ji Hee Kim; Eun Soo Kim; Ha Young Park; Kyueng-Whan Min; Mi Jung Kwon
Journal:  Alzheimers Res Ther       Date:  2022-07-01       Impact factor: 8.823

2.  Potentially Inappropriate Medication Use in Patients with Dementia.

Authors:  Kyungwon Yoon; Jung-Tae Kim; Won-Gun Kwack; Donghyun Kim; Kyung-Tae Lee; Seungwon Yang; Sangmin Lee; Yeo-Jin Choi; Eun-Kyoung Chung
Journal:  Int J Environ Res Public Health       Date:  2022-09-10       Impact factor: 4.614

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.